Patents by Inventor Yuzuru Ikehara
Yuzuru Ikehara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160139039Abstract: An imaging system includes an infrared camera 10 that is sensitive to light beams having wavelengths in an infrared region, a lighting unit 20 that emits light beams having multiple wavelengths in an infrared region in a region including the wavelengths to which the infrared camera is sensitive, and a control unit 30 that controls capture of an image by the infrared camera 10 and emission of a light beam by the lighting unit 20.Type: ApplicationFiled: November 25, 2015Publication date: May 19, 2016Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NIKON CORPORATIONInventors: Yuzuru IKEHARA, Mutsuo OGURA, Susumu MAKINOUCHI
-
Patent number: 9254397Abstract: The present invention provides a plasma evaluation system and method for evaluating plasma, including: a treatment target material and a weak current measurement unit including a resistor unit and a differential amplifier, wherein the treatment target material is connected to the weak current measurement unit via a treatment target side measurement terminal, the resistor unit of the weak current measurement unit is connected to a ground side of a plasma generation current source, and the system and method evaluate plasma by receiving plasma generated by a plasma treatment equipment with the treatment target material, measuring a current by measuring a voltage across resistors of the resistor unit through the differential amplifier, and measuring an output voltage of the plasma generation power source.Type: GrantFiled: October 22, 2012Date of Patent: February 9, 2016Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Hajime Sakakita, Yuzuru Ikehara, Satoru Kiyama
-
Publication number: 20150338396Abstract: It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.Type: ApplicationFiled: August 9, 2013Publication date: November 26, 2015Inventors: Hisashi NARIMATSU, Atsushi KUNO, Yuzuru IKEHARA, Yasuhiro HASHIMOTO, Keiro SHIROTANI, Kiyomitsu NARA, Yoshinobu KARIYA, Hiromi ITO, Kyoka HOSHI
-
Publication number: 20150293104Abstract: An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein.Type: ApplicationFiled: July 12, 2012Publication date: October 15, 2015Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Hirofumi Nozaki, Takashi Ohkura, Atsushi Kuno, Maki Sogabe, Tomomi Kubota, Hiroyuki Kaji, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hayao Nakanishi, Toru Nakanishi
-
Publication number: 20140323324Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.Type: ApplicationFiled: December 16, 2011Publication date: October 30, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
-
Publication number: 20140312241Abstract: [Problem] To provide a system and a method for objectively evaluating plasma by easily measuring a current generated by a plasma treatment equipment for medical purposes, etc., and a current flowing through a living body, etc. [Solution] A plasma evaluation system and method for evaluating plasma, including: a treatment target material; and a weak current measurement unit including a resistor unit and a differential amplifier, wherein the treatment target material is connected to the weak current measurement unit via a treatment target side measurement terminal, the resistor unit of the weak current measurement unit is connected to a ground side of a plasma generation current source, and the system and method evaluate plasma by receiving plasma generated by a plasma treatment equipment with the treatment target material, measuring a current by measuring a voltage across resistors of the resistor unit through the differential amplifier, and measuring an output voltage of the plasma generation power source.Type: ApplicationFiled: October 22, 2012Publication date: October 23, 2014Inventors: Hajime Sakakita, Yuzuru Ikehara, Satoru Kiyama
-
Publication number: 20140295455Abstract: The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-?1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.Type: ApplicationFiled: July 26, 2012Publication date: October 2, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
-
Publication number: 20140242607Abstract: It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-?1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.Type: ApplicationFiled: July 26, 2012Publication date: August 28, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
-
Publication number: 20140057286Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease.Type: ApplicationFiled: October 11, 2013Publication date: February 27, 2014Applicants: Sysmex Corporation, National Center for Global Health and Medicine, Nagoya City University, National Institute of Advanced Industrial Science and TechnologyInventors: Hisashi Narimatsu, Yuzuru Ikehara, Atsushi Kuno, Maki Sogabe, Yasuhito Tanaka, Masashi Mizokami, Kiyoaki Ito, Shunsuke Matsubara, Chikayuki Tsuruno, Youichi Takahama, Takashi Kagawa, Shinya Nagai
-
Patent number: 8623608Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.Type: GrantFiled: January 13, 2012Date of Patent: January 7, 2014Assignees: Sysmex Corporation, National Institute of Advanced Industrial Science and Technology, Nagoya University, National Center for Global Health and MedicineInventors: Hisashi Narimatsu, Yuzuru Ikehara, Atsushi Kuno, Maki Sogabe, Yasuhito Tanaka, Masashi Mizokami, Kiyoaki Ito, Shunsuke Matsubara, Chikayuki Tsuruno, Youichi Takahama, Takashi Kagawa, Shinya Nagai
-
Publication number: 20130288272Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.Type: ApplicationFiled: September 9, 2011Publication date: October 31, 2013Applicants: TOKYO MEDICAL UNIVERSITY, NATIONAL INSTIUTE OF ADVANCED INDUSTRIAL SCIENCE AInventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
-
Patent number: 8557602Abstract: Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit thereof. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.Type: GrantFiled: February 23, 2010Date of Patent: October 15, 2013Assignees: National Institute of Advanced Industrial Science and Technology, University of TsukubaInventors: Atsushi Kuno, Jun Hirabayashi, Atsushi Matsuda, Hisashi Narimatsu, Yuzuru Ikehara, Junichi Shoda, Toru Kawamoto
-
Publication number: 20130204244Abstract: A plasma treatment equipment includes: a plasma starting and stabilizing unit (A) having an insulating material such as a dielectric material having an elongated hole connecting to a plasma ejection portion, a triggering and discharge-stabilizing electrode, and an intense electric field electrode mounted thereon; and a plasma generating unit (B) including the insulating material having the elongated hole and a plasma generating electrode configured to perform main plasma generation at the time of operation, wherein the triggering and discharge-stabilizing electrode, the intense electric field electrode, and the plasma generating electrode are provided in such a manner that all the electrodes are not exposed and covered with the dielectric material for the entire space of one or more of the elongated hole which allows passage of gas from the upstream, starting of the plasma and generation of the plasma, and ejection of the plasma jet.Type: ApplicationFiled: June 27, 2011Publication date: August 8, 2013Inventors: Hajime Sakakita, Yuzuru Ikehara, Satoru Kiyama
-
Publication number: 20120190576Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.Type: ApplicationFiled: July 12, 2010Publication date: July 26, 2012Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami
-
Publication number: 20120172247Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.Type: ApplicationFiled: January 13, 2012Publication date: July 5, 2012Inventors: Hisashi Narimatsu, Yuzuru Ikehara, Atsushi Kuno, Maki Sogabe, Yasuhito Tanaka, Masashi Mizokami, Kiyoaki Ito, Shunsuke Matsubara, Chikayuki Tsuruno, Youichi Takahama, Takashi Kagawa, Shinya Nagai
-
Publication number: 20120065089Abstract: Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit therefor. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.Type: ApplicationFiled: February 23, 2010Publication date: March 15, 2012Applicants: University of Tsukuba, National Institute of Advanced Industrial Science and TechnologyInventors: Atsushi Kuno, Jun Hirabayashi, Atsushi Matsuda, Hisashi Narimatsu, Yuzuru Ikehara, Junichi Shoda, Toru Kawamoto
-
Publication number: 20090238863Abstract: It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen substance and is used to cause the MHC class I and class II molecules of an antigen-presenting cell to present an antigen peptide.Type: ApplicationFiled: March 29, 2006Publication date: September 24, 2009Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, AICHI PREFECTUREInventors: Naoya Kojima, Yuzuru Ikehara, Kunio Tsujimura
-
Publication number: 20080020029Abstract: The object of the present invention is to provide a drug delivery composition which allows efficient accumulation of an administered substance such as an anti-cancer drug and the like in a target site. The present invention provides a drug delivery liposome composition for delivering a substance to be administered to a target site, which comprises an oligosaccharide coated liposome and a substance to be administered.Type: ApplicationFiled: March 17, 2005Publication date: January 24, 2008Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, AICHI PREFECTUREInventors: Naoya Kojima, Yoshitaka Shimizu, Yuzuru Ikehara, Hayao Nakanishi